Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 147 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR What to Know About Kidney Cancer Genetic Conditions and Genetic Counseling June 9, 2021 FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer July 26, 2018 Young Mom Gives Birth To Healthy Baby Boy In The Midst... June 26, 2020 Countdown to 100,000 OncoLife Survivorship Care Plans: How it all started February 19, 2021 Load more HOT NEWS For HPV-Positive Women, Test Can Guide Cervical Cancer Screening Follow-Up The long road to targeting the holy grail of the immune... New Research in Treating Metastatic Breast Cancer, Preventing Breast Cancer, and... Prising open the trap: Getting to grips with targeted cancer drug...
